Oramed Pharmaceuticals Statistics
Total Valuation
ORMP has a market cap or net worth of $94.41 million. The enterprise value is -$16.02 million.
| Market Cap | 94.41M |
| Enterprise Value | -16.02M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ORMP has 40.52 million shares outstanding. The number of shares has increased by 4.02% in one year.
| Shares Outstanding | 40.52M |
| Shares Change (YoY) | +4.02% |
| Shares Change (QoQ) | +2.68% |
| Owned by Insiders (%) | 11.23% |
| Owned by Institutions (%) | 13.86% |
| Float | 36.70M |
Valuation Ratios
The trailing PE ratio is 16.64.
| PE Ratio | 16.64 |
| Forward PE | n/a |
| PS Ratio | 70.46 |
| Forward PS | 46.28 |
| PB Ratio | 0.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.32.
| Current Ratio | 3.06 |
| Quick Ratio | n/a |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 6.65 |
| Debt / FCF | n/a |
| Interest Coverage | 3.71 |
Financial Efficiency
Return on equity (ROE) is 3.60% and return on invested capital (ROIC) is -7.32%.
| Return on Equity (ROE) | 3.60% |
| Return on Assets (ROA) | 2.90% |
| Return on Capital (ROIC) | -7.32% |
| Revenue Per Employee | $103,077 |
| Profits Per Employee | $425,000 |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.64% in the last 52 weeks. The beta is 1.82, so ORMP's price volatility has been higher than the market average.
| Beta (1Y) | 1.82 |
| 52-Week Price Change | +2.64% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 2.67 |
| Relative Strength Index (RSI) | 36.93 |
| Average Volume (30 Days) | 174,737 |
Short Selling Information
The latest short interest is 583,943, so 1.44% of the outstanding shares have been sold short.
| Short Interest | 583,943 |
| Short Previous Month | 484,014 |
| Short % of Shares Out | 1.44% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 3.95 |
Income Statement
In the last 12 months, ORMP had revenue of $1.34 million and earned $5.53 million in profits. Earnings per share was $0.14.
| Revenue | 1.34M |
| Gross Profit | 1.34M |
| Operating Income | -15.77M |
| Pretax Income | 5.53M |
| Net Income | 5.53M |
| EBITDA | 7.76M |
| EBIT | 7.56M |
| Earnings Per Share (EPS) | $0.14 |
Balance Sheet
The company has $162.05 million in cash and $51.62 million in debt, giving a net cash position of $110.43 million or $2.73 per share.
| Cash & Cash Equivalents | 162.05M |
| Total Debt | 51.62M |
| Net Cash | 110.43M |
| Net Cash Per Share | $2.73 |
| Equity / Book Value | 163.82M |
| Book Value Per Share | 4.04 |
| Working Capital | 109.37M |
Cash Flow
In the last 12 months, operating cash flow was -$10.30 million and capital expenditures -$254,000, giving a free cash flow of -$10.55 million.
| Operating Cash Flow | -10.30M |
| Capital Expenditures | -254,000 |
| Free Cash Flow | -10.55M |
| FCF Per Share | -$0.26 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,176.79% and 412.31%.
| Gross Margin | 100.00% |
| Operating Margin | -1,176.79% |
| Pretax Margin | 412.31% |
| Profit Margin | 412.31% |
| EBITDA Margin | 578.96% |
| EBIT Margin | 564.33% |
| FCF Margin | -787.24% |
Dividends & Yields
ORMP does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.02% |
| Shareholder Yield | -4.02% |
| Earnings Yield | 5.85% |
| FCF Yield | -11.17% |
Analyst Forecast
The average price target for ORMP is $2.00, which is -14.16% lower than the current price. The consensus rating is "Hold".
| Price Target | $2.00 |
| Price Target Difference | -14.16% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 23, 2013. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jan 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
ORMP has an Altman Z-Score of 0.7 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.7 |
| Piotroski F-Score | 3 |